A Phase 3 interventional study of RPH-104 and Placebo in Adult-Onset Still's Disease and AOSD, sponsored by R-Pharm International, LLC. Withdrawn at 4 sites in Russian Federation. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-11-15.
Sponsored by R-Pharm International, LLC (part of R-Pharm) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The primary objective of the study is to evaluate the efficacy of RPH-104 when administered at a dose of 160 mg on Day 0, Day 7, Day 21 and then once every 2 weeks (Q2W) subcutaneous (SC) in patients with Adult Onset Still's Disease (AOSD). Furthermore, the study is scheduled to investigate pharmacokinetic (PK) and pharmacodynamic (PD) parameters of RPH-104.
The overall study will include the following periods:
Baseline characteristics will be evaluated on Study Day 0. Assessment of efficacy (treatment response) and safety will be performed at Visit 2 (Day 7), Visit 3 (Day 21), Visit 4 (Day 35) and then every 4 weeks during the run-in period. A response to therapy during this period is the achievement of low activity/inactive disease including no exacerbations of AOSD.
The subjects who achieve and preserve low activity/inactive disease for at least 8 weeks under mono therapy with RPH-104 (i. e. previous therapy has been permanently discontinued) or combination of RPH-104 and GC at dose achieved in reduction (7.5 mg/day or less), stable for at least 4 weeks can be switched to the randomized withdrawal period.
Efficacy and safety assessment during the randomized withdrawal period will be performed every 4 weeks. During this period the investigational product/placebo will be administered to the subjects every 2 weeks - at visits to the study site - by the qualified medical staff (or a subject monitored by the staff) or at home by the subjects themselves. In case of self-administration of the investigational product/placebo by a subject during the randomized withdrawal period, additional conditions will be created to prevent from unblinding.
The subjects who terminated therapy with RPH-104 early (for any reasons in any treatment period) will be prescribed with other products selected by the investigator and will have to make safety follow-up visits in 2 and 8 weeks after the last dosing with the investigational product.
Maximum possible duration of study per patient will be 144 weeks.
It is planned to randomize totally 36 patients with AOSD in the study (18 patients per group). Given potential withdrawal at the screening and during the run-in period, the number of screened patients (who signed informed consent) will be totally about 53 screened patients.
23 studies on the registry are indexed under Still's Disease, Adult-Onset; 5 are open to participants now.
Browse Still's Disease, Adult-Onset studies →R-Pharm International, LLC is the lead sponsor of 17 studies on the registry; 4 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
OR Consent of male subjects leading active sexual life to use highly efficient contraceptive measures throughout the study starting from the moment of signing the Informed Consent Form and for at least 8 weeks after the study product discontinuation.
Highly effective contraceptive method is defined as follows:
combination of any two of the following methods (a+b or a+c or b+c):
Exclusion Criteria:
Previous administration of:
Conditions or signs which, according to the investigator, suggest impaired (reduced) immune response and/or significantly increase the risk of immunomodulating therapy including (but not limited to):
Active infection of M. Tuberculosis, as per examination results: positive QuantiFERON-TB/SPOT.TB test at screening, chest X-ray findings confirming pulmonary tuberculosis during screening.
* At discretion of certified tuberculosis specialist or pulmonologist specialized in diagnosing and treatment of tuberculosis, a patient with latent tuberculosis can be included in the study during the preventative treatment of latent tuberculosis infection with isoniazid or rifampicin (the choice of preventive therapy is made by a phthisiatrician, taking into account , drug interactions and risks of adverse reactions in a particular patient).
Any of the deviations in the laboratory tests below:
Previous participation in this clinical study if at least one dose of the investigational product has been received.
MAS criteria: Fever and hyperferritinemia > 684 ng/mL combined with at least 2/4 criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The investigational product RPH-104 as SC injections at a dose of 160 mg on Day 0, Day 7, Day 21 and then once every 2 weeks (Q2W).
Biological: RPH-104
placebo SC Q2W (equivalent to investigational product volume)
Drug: Placebo
solution for subcutaneous administration 40 mg/mL, 2 mL in the 4-mL glass vial
Also known as: goflikicept, Arcerix
Normal Saline (0.9% Sodium Chloride solution)
Time (number of days) to exacerbation during 24 weeks after randomization while taking RPH-104 vs placebo in patients with AOSD
The criteria for exacerbation are (more than 2 criteria or worsening of more than 2 previous criteria): * fever (body temperature ≥ 38.0 °C) due to AOSD during a week before the visit; * rash typical of AOSD; * clinical disease activity index (CDAI) \> 2.8 for subjects with inactive disease; \> 10 for subjects with low disease activity\*; * sore throat\*; * pericardial effusion ≥ 7 mm\*; * pleuritis\*; * chest pain \> 3 numeric rating scale (NRS)\*; * C-reactive protein (CRP) \> 5 mg/L\*; * aminotransferase (ALT, AST) level \> 3 x upper limits of normal (ULN)\*; * leukocyte count \> 10 x 10\^9/L with \> 80 % polymorphonuclear neutrophils\*; * ferritin level \> 3 x ULN\*; * Patient's Global Assessment (PtGA) worsening by 2 cm and more; * Physician's Global Assessment (PGA) worsening by 2 cm and more; * myalgia\*; * hepatomegaly\*; * splenomegaly\*; * lymphadenopathy\*. \* Increase/presence of noted signs due to other reason than AOSD should not be considered in the activity assessment for AOSD exacerbation.
Time frame: from randomization (visit 16, week 29) to exacerbation, up to week 53
Proportion of patients from RPH-104 group who developed AOSD exacerbation during 24 weeks after randomization vs placebo
The criteria for exacerbation are (more than two criteria or worsening of more than two previous criteria): * fever, i. e. body temperature ≥ 38.0 °C due to AOSD lasting at least two consecutive days; * rash typical of AOSD; * sore throat\*; * pericardial effusion ≥ 7 mm\*; * pleuritis\*; * aminotransferase (ALT, AST) level \> 3 x ULN\*; * leukocyte count \> 15 x 10\^9/L\*; * ferritin level \> 3 x ULN\*; * myalgia\*; * hepatomegaly\*; * splenomegaly\*; * lymphadenopathy\*; * pneumonia\*; * arthritis\*. \* Increase/presence of noted signs due to other reason than AOSD should not be considered in the activity assessment for AOSD exacerbation.
Time frame: up to week 53
Proportion of patients who developed AOSD exacerbation during the run-in period
The criteria for exacerbation are (more than two criteria or worsening of more than two previous criteria): * fever, i. e. body temperature ≥ 38.0 °C due to AOSD lasting at least two consecutive days; * rash typical of AOSD; * sore throat\*; * pericardial effusion ≥ 7 mm\*; * pleuritis\*; * aminotransferase (ALT, AST) level \> 3 x ULN\*; * leukocyte count \> 15 x 10\^9/L\*; * ferritin level \> 3 x ULN\*; * myalgia\*; * hepatomegaly\*; * splenomegaly\*; * lymphadenopathy\*; * pneumonia\*; * arthritis\*. \* Increase/presence of noted signs due to other reason than AOSD should not be considered in the activity assessment for AOSD exacerbation.
Time frame: up to week 29
Proportion of patients with fever resolution
Proportion of patients with fever resolution during the run-in treatment period. Fever resolution means body temperature \< 38.0 °C
Time frame: up to Day 14
Proportion of patients with Simple disease activity index (SDAI) ≤ 3.3
Proportion of patients with SDAI ≤ 3.3 during the run-in treatment period. SDAI is the sum of five parameters: * Physician's Global Assessment (PGA) and * Patient's Global Assessment (PtGA) * C-Reactive Protein (CRP) level\* * Number of joints with active arthritis (based on an assessment of 28 joints): Tender Joint Count (TJC) (0-28) + Swollen Joint Count (SJC) (0-28) + PtGA (Visual analogue scale (VAS) in cm) + PGA (VAS) + CRP (mg/dl) The maximum score is 86 with high disease activity (the worst outcome). \*Another cause for the elevated CRP must be ruled out.
Time frame: up to Day 203
Proportion of patients with CDAI 3.3 - 11
Proportion of patients with CDAI 3.3 - 11 during the run-in treatment period. CDAI will be calculated using the following formula: CDAI = tender joint number (TJN) (0-28) + swollen joint number (SJN) (0-28) + Patient Global Assessment of Disease Activity (Visual analogue scale (VAS) in cm) + Physician Global Assessment (VAS in cm). CDAI Range: 0 - 76, with a decrease from baseline indicating improvement.
Time frame: up to Day 203
Proportion of patients with a decrease in modified Pouchot score (mPouchot) score of at least 3 points or a decrease in mPouchot score of at least 1 point, provided that mPouchot score ≤4 at baseline (Day 0), during the run-in treatment period
mPouchot score is calculated by assigning 1 point to each of these items: * fever (body temperature ≥ 38.0 °C due to AOSD); * rash typical of AOSD (according to data of physical examination); * number of joints with active arthritis (0 to 68/66 joints)\*; * sore throat (according to complaints as of examination)\*; * pericardial effusion (Echocardiography)\*; * pleuritis (ultrasound examination of the lungs)\*; * aminotransferase (ALT, AST) activity\*; * leukocyte count\*; * ferritin level\*; * myalgia (according to complaints as of examination)\*; * hepatomegaly (ultrasound examination of the abdominal organs)\*; * lymphadenopathy (physical examination)\*; * Pneumonia (chest X-ray data)\*. The maximum score is 12 points with high disease activity (the worst outcome). Hepatomegaly and aminotransferase levels are 1 point. * For noted signs, which are not AOSD-specific, other reason for their increase/presence should be considered in the activity assessment for AOSD exacerbation.
Time frame: up to Day 203
Proportion of patients with clinically significant reduction in joint manifestations
Proportion of patients with clinically significant reduction in joint manifestations - SDAI reduced by at least 7 points from baseline (Day 0), during the run-in treatment period.
Time frame: up to Day 203
Start is estimated for Dec 2023; primary completion for Aug 2025, 20 months later.
How these figures are worked out, and which studies are left out of them.
This study is withdrawn, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Goflikicept
Still's Disease, Adult-Onset →